Back

12-Month effect of Tafamidis on the clinical progression of cardiac amyloidosis in a single centre cohort

12 May 2024 (12:12 - 13:48)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy 3 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ricardo Carvalheiro

University Hospital Lisboa Central, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
The role of intermittent levosimendan infusions in patients with advanced heart failure: is it enough?
Doctor I. Gomes Campos (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of complete evidence-based treatment implementation at hospital discharge of acute heart failure with reduced LVEF in a real-world population
Doctor S. Ruiz Bustillo (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Optimizing heart failure management: impact of quadruple therapy initiation at discharge following decompensation events in patients with reduced ejection fraction
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Tolerance and clinical response to SGL2 inhibitors in Fabry disease
Doctor I. Mattig (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy 3

The Event

Event poster

Heart Failure 2024

12 May 2024 12:12 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
thumbnail
Congress Presentation
How did a three-year tafamidis therapy course affect our patient's life?
thumbnail
Congress Session
Advances in amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources